cffbefceeb

Kenneth Smith

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Kenneth Smith

  • uploads///BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb’s Key Products Performed in 1Q18

    Total sales for Bristol-Myers Squibb’s Opdivo increased 34%, from $1.1 billion in 1Q17 to $1.5 billion in 1Q18.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    A Look at Sarepta Therapeutics’ Stock Performance

    After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.

    By Kenneth Smith
  • uploads///Spark pipeline
    Company & Industry Overviews

    How Spark Therapeutics Is Positioned in 2018

    Spark Therapeutics generated revenues of $25.18 million in the second quarter of 2018 compared to $1.48 million in Q2 2017.

    By Kenneth Smith
  • uploads///AXDX analysts Reco
    Company & Industry Overviews

    What Analysts Recommend for Accelerate Diagnostics and Peers

    Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///ABBV
    Company & Industry Overviews

    Analyzing AbbVie’s Financial Performance

    AbbVie (ABBV) generated net revenue of $7.9 billion in 1Q18 compared to $6.5 billion in 1Q17.

    By Kenneth Smith
  • uploads///TSRO
    Company & Industry Overviews

    Gauging Analysts’ Views on Tesaro Stock

    In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.

    By Kenneth Smith
  • uploads///BGNE
    Company & Industry Overviews

    Do Analysts See Any Upside in BeiGene Stock?

    Of the 11 analysts covering BeiGene (BGNE), four have given it “strong buys,” and seven have given it “buys.”

    By Kenneth Smith
  • uploads///Spark ana reco
    Company & Industry Overviews

    What Spark Therapeutics’ Valuation Trend Indicates

    Spark Therapeutics’ (ONCE) operating expenses decreased from $78.48 million in Q2 2017 to $59.78 million in Q2 2018.

    By Kenneth Smith
  • uploads///Sucampo Revenue Growth
    Company & Industry Overviews

    Key Risks Facing Sucampo Pharmaceuticals in 2017

    Sucampo has taken on a significant level of debt. Its outstanding debt is ~$300 million. Its interest expense has increased from $6.8 million in 2015 to $23.7 million in 2016.

    By Kenneth Smith
  • uploads///Sucampo pipeline pre
    Company & Industry Overviews

    Sucampo Pharmaceuticals’ Research Pipeline in December 2017

    Sucampo Pharmaceuticals (SCMP) recently completed a Phase 3 study for the alternate sprinkle formulation of Amitiza (lubiprostone) in adults with CIC (chronic idiopathic constipation).

    By Kenneth Smith
  • uploads///Novavax RSV Pipeline
    Company & Industry Overviews

    Exploring Novavax’s Vaccine Candidates for RSV

    According to Novavax, ~64.0 million RSV infections occur every year on a global basis. The global cost of RSV exceeds $88.0 billion.

    By Kenneth Smith
  • uploads///coinsquare market share
    Company & Industry Overviews

    Riot Blockchain’s Recent Investments in the Cryptocurrency Space

    In October 2017, Riot Blockchain (RIOT) acquired a 52% stake in Tess, a developer of blockchain solutions for telecom (telecommunications) companies.

    By Kenneth Smith
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///ABMD
    Company & Industry Overviews

    Examining Abiomed’s Gross Margin Trend

    In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million.

    By Kenneth Smith
  • uploads///AZN
    Company & Industry Overviews

    Major Expected Events from AstraZeneca’s R&D in H2 2018

    AstraZeneca has seen major recent product approvals such as Lynparza in Japan for breast cancer and Tagrisso in the EU for lung cancer.

    By Kenneth Smith
  • uploads///Ignyta Pipeline
    Company & Industry Overviews

    Ignyta’s Drug Pipeline

    Ignyta (RXDX) has completed enrollment for a Phase 1 clinical trial of RXDX-105, an orally bioavailable small molecule tyrosine kinase inhibitor.

    By Kenneth Smith
  • uploads///Ignyta RD Expenses
    Company & Industry Overviews

    Inside Ignyta’s Financial Performance

    Ignyta’s (RXDX) R&D (research and development) expenses increased from $16.6 million in 3Q16 to $21.7 million in 3Q17, a 30% rise.

    By Kenneth Smith
  • uploads///Ignyta risks
    Company & Industry Overviews

    Ignyta and Its Key Risks in 2018

    In October 2017, Ignyta (RXDX) raised $150 million by issuing 10 million shares of its common stock.

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries.

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    Do Analysts See Any Upside for Thermo Fisher Stock?

    Of the 17 analysts covering Thermo Fisher Scientific (TMO), 14 recommend ” buy” or a higher rating, and three recommend “hold.”

    By Kenneth Smith
  • uploads///TMO
    Company & Industry Overviews

    Thermo Fisher Scientific’s Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///cells _
    Company & Industry Overviews

    Taking Stock of BeiGene’s Latest Performance

    BeiGene is a company focused on bringing to market molecularly targeted and immuno-oncology drugs for the treatment of cancer.

    By Kenneth Smith
  • uploads///ABMD
    Company & Industry Overviews

    Do Analysts See Any Upside for Abiomed Stock?

    In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    Exploring Abiomed’s Latest Performance Trends

    In this series, we’ll explore Abiomed’s financials and valuation along with analysts’ views on its stock.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    Understanding Sarepta Therapeutics’ Operational Performance

    Sarepta Therapeutics’ (SRPT) R&D (research and development) expenses rose YoY (year-over-year) to $86.58 million.

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Do Analysts See Any Upside for Vertex Stock?

    Of the 25 analysts covering Vertex Pharmaceuticals (VRTX), 21 recommend “buy” or a higher rating, and four recommend “hold.”

    By Kenneth Smith
  • uploads///VRTX
    Company & Industry Overviews

    Vertex Pharmaceuticals’ Gross Margin Trends

    Kalydeco, Orkambi, and Symdeko are Vertex Pharmaceuticals’ (VRTX) products on the market.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Do Analysts See Any Upside for bluebird bio Stock?

    In this year’s third quarter, bluebird bio (BLUE) generated net interest income of $4.59 million.

    By Kenneth Smith
  • uploads///BLUE
    Company & Industry Overviews

    Understanding bluebird bio’s Operational Performance

    In 2018 and 2019, bluebird bio (BLUE) is expected to generate revenues of $43.62 million and $67.0 million, respectively.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///SAGE
    Company & Industry Overviews

    Sage Therapeutics’ Operational Performance

    In fiscal 2018 and fiscal 2019, Sage Therapeutics (SAGE) is expected to generate revenues of $79.41 million and $36.63 million, respectively.

    By Kenneth Smith
  • uploads///nerve cell _
    Company & Industry Overviews

    Sage Therapeutics: Analyzing New Product Candidates

    The Zulresso injection is Sage Therapeutics’ lead product candidate. The company has filed a new drug application.

    By Kenneth Smith
  • uploads///IONS
    Company & Industry Overviews

    Do Analysts See Any Upside for Ionis Stock?

    Of the 14 analysts covering Ionis Pharmaceuticals (IONS), five have given it “buy” or higher ratings, seven have given it “holds.”

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Ionis’s Performance

    Ionis Pharmaceuticals’ (IONS) two business segments are Ionis Core and Akcea Therapeutics, in which Ionis holds a 76% stake.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Do Analysts See Any Upside for Regeneron Stock?

    Of the 26 analysts covering Regeneron Pharmaceuticals (REGN), eight recommend “buy” or a higher rating, 17 recommend “hold,” and one recommends “sell.”

    By Kenneth Smith
  • uploads///SGEN
    Company & Industry Overviews

    What Seattle Genetics’ Bottom-Line Trend Indicates

    In December 2018, of the total 13 analysts covering Seattle Genetics, eight analysts have given Seattle Genetics stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    How’s Seattle Genetics Positioned?

    Seattle Genetics generated total revenues of $169.42 million in the third quarter of 2018 as compared with $135.29 million in the comparable period of 2017.

    By Kenneth Smith
  • uploads///REGN
    Company & Industry Overviews

    Regeneron Pharmaceuticals’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Regeneron Pharmaceuticals (REGN) is expected to generate revenue of $6.49 billion and $7.16 billion, respectively, compared with revenue of $5.87 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///hospital _
    Company & Industry Overviews

    How These Medical Equipment Stocks Have Fared in the Last Month

    In December 2018, of the total 15 analysts covering Align Technology, 13 analysts have given the stock a “buy” or higher rating.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Analysts Remain Bullish on Illumina Stock

    In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Gross Margin Trend

    Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///ILMN
    Company & Industry Overviews

    Understanding Illumina’s Geographical Performance

    For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

    By Kenneth Smith
  • uploads///hypertension _
    Company & Industry Overviews

    Taking Stock of Edwards Lifesciences’ Performance

    A strong operational performance and steady uptick in Edwards Lifesciences’ stock price has kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///XRAY
    Company & Industry Overviews

    What Does Dentsply’s Bottom-Line Trend Indicate?

    Dentsply Sirona’s interest expense decreased marginally from $9.8 million in the third quarter of 2017 to $9.7 million in the third quarter.

    By Kenneth Smith
  • uploads///HOLX
    Company & Industry Overviews

    What Analysts Recommend for Hologic Stock

    In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///SYK
    Company & Industry Overviews

    Analysts Remain Bullish on Stryker Stock

    In November 2018, of the total 29 analysts covering Stryker (SYK), 19 analysts gave Stryker stock a “buy” or higher rating, and ten analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///doctors office _
    Company & Industry Overviews

    How Stryker Is Positioned in November

    Stryker generated total revenues of $3.24 billion in the third quarter of 2018 as compared to $3.01 billion in the comparable period of 2017.

    By Kenneth Smith
  • uploads///checklist _
    Company & Industry Overviews

    Baxter International: Why Investors Are Interested

    Fluctuations in Baxter International’s (BAX) stock price have kept investors interested in the stock in 2018.

    By Kenneth Smith
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///CLVS
    Company & Industry Overviews

    Gauging Analysts’ Views on Clovis Stock

    In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.

    By Kenneth Smith
  • uploads///TNDM
    Company & Industry Overviews

    Why Wall Street Is Still Bullish on Tandem Stock

    This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.

    By Kenneth Smith
  • uploads///diabetes _
    Company & Industry Overviews

    Why Tandem Should Be on Your Stock Radar

    Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.

    By Kenneth Smith
  • uploads///molecule _
    Earnings Report

    How TransEnterix Has Been Performing in November

    In this series, we’ll explore TransEnterix’s financials, analyst recommendations, and valuation metrics.

    By Kenneth Smith
  • uploads///syringe _
    Earnings Report

    How Nektar Performed in the Third Quarter

    Nektar Therapeutics generated total revenues of $27.76 million in the third quarter of 2018 as compared with $152.93 million in the third quarter of 2017.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    How Analysts View Alexion Stock

    In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.

    By Kenneth Smith
  • uploads///ALXN
    Company & Industry Overviews

    Analyzing Alexion Pharmaceuticals’ Product Performance

    Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.

    By Kenneth Smith
  • uploads///GILD
    Company & Industry Overviews

    Gilead Sciences: Analysts’ Recommendations

    In November, six analysts recommended a “strong buy,” ten recommended a “buy,” and 12 recommended a “hold” for Gilead Sciences.

    By Kenneth Smith
  • uploads///SYk ana reco
    Earnings Report

    What Analysts Recommend for Stryker Stock

    Of the total 28 analysts covering Stryker (SYK) in October 2018, 19 analysts have given the stock a “buy” or higher rating, and nine analysts have given Stryker a “hold” rating.

    By Kenneth Smith
  • uploads///NVCR ana reco
    Earnings Report

    Gauging Analysts’ Views for NovoCure Stock

    Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”

    By Kenneth Smith
  • uploads///VAR FCF
    Earnings Report

    What to Expect from Varian’s Bottom Line in Q4 2018

    Varian Medical Systems (VAR) is expected to report net income of $105.05 million in the fourth quarter of fiscal 2018.

    By Kenneth Smith
  • uploads///SRPT
    Company & Industry Overviews

    Analyzing Sarepta’s Product Pipeline

    Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    An Investor’s Overview of Sarepta Therapeutics

    Sarepta Therapeutics’ revenues are forecast to be $302.13 million in 2018 and $430.37 million in 2019, up from $154.58 million in 2017.

    By Kenneth Smith
  • uploads///blood _
    Company & Industry Overviews

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex announced on October 10 that the FDA has lifted the clinical hold and accepted its Investigational New Drug Application for CTX001.

    By Kenneth Smith
  • uploads///capsule _
    Company & Industry Overviews

    How Alexion Pharmaceuticals Is Positioned in October

    In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.

    By Kenneth Smith
  • uploads///ISRG RD
    Earnings Report

    How Intuitive’s Bottom Line Is Expected to Look in Q3 2018

    Intuitive Surgical’s (ISRG) cost of goods sold is expected to rise 16.82% to $265.76 million in the third quarter of 2018.

    By Kenneth Smith
  • uploads///GILD
    Company & Industry Overviews

    Analyzing Gilead Sciences’ Research Pipeline Developments

    On October 3, Gilead Sciences (GILD) reported the results from a phase three study evaluating Biktarvy’s safety and efficacy.

    By Kenneth Smith
  • uploads///RMD ana reco
    Company & Industry Overviews

    What ResMed’s Valuation Trend Indicates

    The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

    By Kenneth Smith
  • uploads///VRAY ana reco
    Company & Industry Overviews

    What ViewRay’s Valuation Trend Indicates

    In September, of the seven analysts covering ViewRay (VRAY), six have given its stock “buy” or higher ratings, and one analyst has given it a “sell” rating.

    By Kenneth Smith
  • uploads///A ana reco
    Company & Industry Overviews

    What’s the Upside Potential for Agilent Technologies Stock?

    In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

    By Kenneth Smith
  • uploads///A
    Company & Industry Overviews

    What’s Driving Agilent Technologies’ Segment Growth?

    Agilent Technologies’ (A) Life Sciences and Applied Markets segment had revenues of $510 million in Q3 2017 compared to $540 million in Q3 2018.

    By Kenneth Smith
  • uploads///molecule _
    Company & Industry Overviews

    Agilent Technologies: Its Acquisition Spree in 2018

    Agilent Technologies (A) has been on an acquisition spree in 2018 with major acquisitions made until the third quarter.

    By Kenneth Smith
  • uploads///WAT ana reco
    Company & Industry Overviews

    What Waters Corporation’s Valuation Trend Indicates

    In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

    By Kenneth Smith
  • uploads///LLY elanco spinoff
    Company & Industry Overviews

    A Look at Eli Lilly’s Elanco Spin-Off

    Eli Lilly (LLY) is expected to post revenues of $24.33 billion in fiscal 2018 and $24.8 billion in fiscal 2019.

    By Kenneth Smith
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Analyzing Perrigo’s Spin-Off of Its Rx Business

    In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

    By Kenneth Smith
  • uploads///laboratory _
    Company & Industry Overviews

    How Quest Diagnostics Is Positioned in 2018

    Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

    By Kenneth Smith
  • uploads///TMO drivres
    Company & Industry Overviews

    What’s Driving the Growth in Thermo Fisher Scientific’s Segments?

    Thermo Fisher Scientific (TMO) operates in four business segments.

    By Kenneth Smith
  • uploads///SLDB pipeline
    Company & Industry Overviews

    Solid Biosciences and Its Focus on Duchenne Muscular Dystrophy

    In the fourth quarter of 2017, Solid Biosciences initiated a Phase 1/2 clinical trial called IGNITE DMD to test SGT-001 in the United States.

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///Biolife revenue trend
    Company & Industry Overviews

    BioLife Solutions: On a Strong Footing

    BioLife Solutions (BLFS) generated revenues of $5.18 million in the second quarter compared to $2.56 million in Q2 2017.

    By Kenneth Smith
  • uploads///TFX
    Company & Industry Overviews

    Analysts Still Bullish on Teleflex Stock

    Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///AZN
    Company & Industry Overviews

    How Did AstraZeneca’s CVRM and Respiratory Products Perform?

    Brilinta’s sales increased by 13.0% to $316.0 million, and Farxiga’s sales grew 34.0% to $340.0 million in the second quarter.

    By Kenneth Smith
  • uploads///VAR
    Company & Industry Overviews

    Here’s What Varian Medical Systems’ Valuation Trend Indicates

    Of the nine analysts covering Varian Medical Systems (VAR) stock, three have given it a “strong buy,” three have given it a “hold,” and three have given it a “sell.”

    By Kenneth Smith
  • uploads///VAR
    Company & Industry Overviews

    Understanding Varian Medical Systems’ Business Segments

    Revenues from the Oncology Systems segment increased from $564.4 million in fiscal Q3 2017 to $667.2 million in fiscal Q3 2018.

    By Kenneth Smith
  • uploads///BAX
    Company & Industry Overviews

    Baxter’s Global Business Units Continue to Deliver

    Baxter International’s (BAX) global business units delivered strong performances in the second quarter.

    By Kenneth Smith
  • uploads///TSRO
    Company & Industry Overviews

    Here’s What Tesaro’s Valuation Trend Indicates

    Tesaro stock has been on a downward trajectory for the past 52 weeks. From a high of $135 on September 5, 2017, it has corrected to $27 in August.

    By Kenneth Smith
  • uploads///NVAX
    Company & Industry Overviews

    Novavax’s Research Pipeline: Key Events to Keep an Eye On

    Novavax’s (NVAX) research pipeline primarily targets the respiratory syncytial virus (or RSV) and seasonal influenza.

    By Kenneth Smith
  • uploads///syringe _
    Company & Industry Overviews

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation, which is the current source of its revenue.

    By Kenneth Smith
  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///ALNY
    Earnings Report

    What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates

    Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///BMY
    Company & Industry Overviews

    What’s the Latest from Bristol-Myers Squibb’s Research Pipeline?

    In May, Bristol-Myers Squibb’s Opdivo and Yervoy combination was approved in Japan for previously untreated patients with unresectable melanoma.

    By Kenneth Smith
  • uploads///EDIT
    Earnings Report

    Why Editas Medicine Stock Fell in July

    Editas Medicine’s (EDIT) general and administrative expenses are expected to rise 39.57% year-over-year in the second quarter.

    By Kenneth Smith
  • uploads///checklist _
    Earnings Report

    How Baxter International Fared in the Second Quarter

    Baxter’s gross profit increased from $1.13 billion in Q2 2017 to $1.24 billion in Q2 2018.

    By Kenneth Smith
  • uploads///aerial view _
    Earnings Report

    What to Expect from Varian Medical Systems’ Q3 2018 Earnings

    Varian Medical Systems (VAR) is expected to report its Q3 2018 earnings on July 25. Analysts expect its revenues to increase 0.30%.

    By Kenneth Smith
  • uploads///thermometer _
    Earnings Report

    What to Expect from Bristol-Myers Squibb’s Q2 2018 Earnings

    Bristol-Myers Squibb (BMY), which is behind blockbuster drugs Opdivo and Eliquis, is set to report its Q2 2018 earnings on July 26.

    By Kenneth Smith
  • uploads///ADXS
    Company & Industry Overviews

    Why Investors Are Excited about Advaxis

    Advaxis (ADXS), in collaboration with Merck (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA.

    By Kenneth Smith
  • uploads///ADXS
    Company & Industry Overviews

    FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis

    In a major development, Advaxis announced on July 13 that the FDA has lifted its hold on the IND (Investigational New Drug) application.

    By Kenneth Smith
  • uploads///ACAD
    Company & Industry Overviews

    Exploring Acadia Pharmaceuticals’ Promising Research Pipeline

    Acadia Pharmaceuticals’ Nuplazid is commercialized in the US market for the treatment of hallucinations and delusions related to Parkinson’s disease psychosis.

    By Kenneth Smith
  • Market Realist Logo

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.